74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
AbbVie Inc
Closed
Sector Healthcare
202.1 0.51
Overview
Share price change
24h
Min
199.16
Max
203.95
Income | -1.6B -22M |
|---|---|
Sales | 642M 15B |
P/E Sector Avg | 82.113 73.394 |
EPS | 2.16 |
Dividend yield | 3.4 |
Profit margin | -0.146 |
Employees | 55,000 |
EBITDA | -70M 4.9B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +3.46 upside |
Dividend yield Sector Avg | 3.40% 3.09% |
|---|---|
Next Earnings | 25 Apr 2025 |
Next Dividend date | 15 May 2025 |
Next Ex Dividend date | 15 Apr 2025 |
Market Cap | 12B 346B |
|---|---|
Previous open | 201.59 |
Previous close | 202.1 |
News Sentiment
By Acuity
24%
76%
52 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
AbbVie Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
AbbVie Inc Forecast
Price Target
By TipRanks
3.46% upside
12 Months Forecast
Average 207.83 USD 3.46%
High 239 USD
Low 165 USD
Based on 18 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.
Sentiment
By Acuity
52 / 393 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AbbVie Inc
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
